Figure 6.
Potent In Vivo Growth Suppression in the Established Orthotopic CFPAC1 Model by PD-L1-Targeted CAR T Cells
(A) A detailed treatment schedule of the orthotopic model. (C) Mean body weight curve of individual CFPAC1 orthotopic models over time. At the endpoint (day 50), mouse groups treated with PD1ACR-T and PDL1CAR-T cells were significantly mitigated compared with those in control groups, respectively (n = 6 per group; ∗p < 0.05). (B and D–F) The endpoint dissection of treated mice. Whole-body appearance (B), overall survival curve (D), pancreatic tumor masses (E), mean tumor volume (mm3) plotted in the bar graph, and mean tumor weight (mg) expressed in line plots (F) from each treated mouse group (n = 6 per group; ∗∗∗p < 0.001).